Volociximab
- Generic Name
- Volociximab
- Drug Type
- Biotech
- CAS Number
- 558480-40-3
- Unique Ingredient Identifier
- 496K5Z02NW
- Indication
Investigated for use/treatment in solid tumors, renal cell carcinoma, melanoma, pancreatic cancer, lung cancer, and ovarian cancer.
A Phase 1 Ascending and Parallel Group Trial to Establish the Safety, Tolerability and Pharmacokinetics Profile of Volociximab (Alpha 5 Beta 1 Integrin Antagonist) in Subjects With Neovascular Age- Related Macular Degeneration
- Conditions
- Age-related Macular Degeneration
- First Posted Date
- 2008-10-31
- Last Posted Date
- 2024-02-21
- Lead Sponsor
- Ophthotech Corporation
- Target Recruit Count
- 63
- Registration Number
- NCT00782093
A Phase 2, Single-Arm Study of Volociximab Monotherapy in Subjects With Platinum-Resistant Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer
- First Posted Date
- 2007-08-16
- Last Posted Date
- 2012-08-23
- Lead Sponsor
- Facet Biotech
- Target Recruit Count
- 16
- Registration Number
- NCT00516841
- Locations
- 🇺🇸
UCI Medical Center, Orange, California, United States
🇺🇸Sharp Hospital, San Diego, California, United States
🇺🇸UCLA JCCC Clinical Research Unit, Los Angeles, California, United States
A Study of Volociximab in Combination With Gemcitabine in Metastatic Pancreatic Cancer
- First Posted Date
- 2006-11-20
- Last Posted Date
- 2013-01-30
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 40
- Registration Number
- NCT00401570
- Locations
- 🇬🇧
Site Reference ID/Investigator# 70536, Manchester, United Kingdom
🇬🇧Site Reference ID/Investigator# 70534, Glasgow, United Kingdom
🇺🇸Site Reference ID/Investigator# 70538, Pittsburgh, Pennsylvania, United States
A Study of Volociximab in Metastatic Melanoma
- First Posted Date
- 2006-08-29
- Last Posted Date
- 2012-04-27
- Lead Sponsor
- Abbott
- Target Recruit Count
- 19
- Registration Number
- NCT00369395
- Locations
- 🇺🇸
Site Reference ID/Investigator# 70376, Boston, Massachusetts, United States
🇺🇸Site Reference ID/Investigator# 70356, La Jolla, California, United States
🇺🇸Site Reference ID/Investigator# 70375, Aurora, Colorado, United States
Study of M200 (Volociximab) in Patients With Metastatic Renal Cell Carcinoma (RCC)
- Conditions
- Renal Cell CarcinomaMetastases
- Interventions
- First Posted Date
- 2005-01-05
- Last Posted Date
- 2012-04-27
- Lead Sponsor
- Abbott
- Target Recruit Count
- 48
- Registration Number
- NCT00100685
- Locations
- 🇺🇸
Site Reference ID/Investigator# 70400, Los Angeles, California, United States
🇺🇸Site Reference ID/Investigator# 70399, Cleveland, Ohio, United States
🇺🇸Site Reference ID/Investigator# 70401, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.